The Pharmacist’s Corner: Clopidogrel dosing and genetic variations

By Rachel Sass, PharmD Should providers increase the clopidogrel dose in patients with decreased functioning CYP2C19 enzymes? Clopidogrel (Plavix) is one of the most well studied medications in pharmacogenetics.  Clopidogrel is a prodrug, meaning that it needs to be converted to an active metabolite in the body to have an effect. This metabolizing process occurs in part via the polymorphic … Read More